Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474926 | 1.00 | SPHK1 (0.49) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL16186835 | 0.90 | SPHK1 (0.50) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL18826477 | 0.90 | SPHK1 (0.50) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL19131760 | 0.90 | SPHK1 (0.50) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL14569203 | 0.89 | SPHK1 (0.49) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL31526733 | 0.87 | SPHK1 (0.45) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL15925967 | 0.85 | SPHK1 (0.48) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL16028097 | 0.85 | SPHK1 (0.57) | SPHK1BRD4 | |
| SCHEMBL16053954 | 0.85 | SPHK1 (0.57) | SPHK1BRD4 | |
| SCHEMBL16070815 | 0.85 | SPHK1 (0.57) | SPHK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2685982-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2685982-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9221826-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2685982-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005146-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-02 | — | — | US | disclosed |
| WO-2012125887-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| CN-1671690-A | Antimicrobial azabicyclic derivatives, compositions and uses thereof | PROCTER & GAMBLE (US) | 2005-09-21 | — | — | CN | disclosed |
| EP-1341781-B1 | ANTIMICROBIAL QUINOLONES | PROCTER & GAMBLE (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900224-B2 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1532137-A2 | ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2004014893-A2 | ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029882-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE CO. | 2004-02-12 | — | — | US | disclosed |
| US-6645981-B2 | For therapy of microbial infection | THE PROCTER & GAMBLE COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-1341781-A1 | ANTIMICROBIAL QUINOLONES | THE PROCTER & GAMBLE COMPANY (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2002048138-A1 | ANTIMICROBIAL QUINOLONES | THE PROCTER & GAMBLE COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | SPHK1 4612/4885BRD4 1366/4885HCRTR2 4592/4885 |
| US-20140005146-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | SPHK1 897/4885BRD4 619/4885HCRTR2 4862/4885 |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | SPHK1 4612/4885BRD4 1366/4885HCRTR2 4592/4885 |
| US-20040029882-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | SPHK1 4612/4885BRD4 1366/4885HCRTR2 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.